Value through Innovation15 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

02.09.2013

Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial, and their respiratory pipeline products in COPD, asthma, IPF and lung cancer at ERS 2013

- For media outside the UK, US and Canada
02.09.2013

New treatment for cats with chronic kidney disease: Boehringer Ingelheim launches Semintra®

26.08.2013

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

- For media outside of the US, the UK & Canada only
16.08.2013

Boehringer Ingelheim takes a further step to establish Animal Health business in Asia

15.08.2013

Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials

- For media outside USA, UK and Canada only
15.08.2013

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

- For Non-US and Non-UK Media
14.08.2013

First half year 2013: Boehringer Ingelheim remains on growth path

01.08.2013

Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

- For non U.S. Media Only
31.07.2013

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

- For Non-US and Non-UK Media
26.07.2013

Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union

- For non U.S. Media Only
17.07.2013

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

16.07.2013

Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure

- For media outside of the US, the UK & Canada only
16.07.2013

Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study

15.07.2013

U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations

- For non U.S. Media Only
10.07.2013

Boehringer Ingelheim and Ashoka Changemakers Announce Winners of Transforming Health Systems Competition

08.07.2013

Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

25.06.2013

Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA

- For Non-U.S. and Non-UK media
24.06.2013

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE

- For media outside of the U.S., the UK & Canada only